🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise globally, with data suggesting more than 82 million new cases each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the face of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

One new antibiotic, also known as a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to major issues, including infertility. Scientists believe that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Global Access

Based on data published in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the current standard treatment, which involves two antibiotics. The trial involved over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors on the front lines have voiced positive views. The availability of a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is viewed as essential to alleviate the strain of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.